期刊文献+

“双通道”模式下S省国谈药可获得性分析 被引量:8

Analysis on the Availability of State-negotiated Drugs in S Province under the"Dual Channel"Model
下载PDF
导出
摘要 目的:分析S省国谈药“双通道”管理实施现状,并就影响可获得性的因素进行分析,为各地完善相关政策、提高患者用药可获得性提供参考借鉴。方法:数据来源于S省国谈药监测平台,查询官方政策文件和报道分析现状,并采用Excel和世界卫生组织/国际健康行动机构(WHO/HAI)标准调查法进行可获得性分析。结果:S省国谈药“双通道”管理取得初步成效,药品总体可获得性在提高,但不同机构、不同疾病的药品可获得性存在差异,部分品种的可获得性普遍较低。影响可获得性的因素包括政策协同、医疗机构诊疗水平和信息系统建设。结论:建议完善医药机构建设,统筹区域发展;建立沟通协同机制,加强监督管理;构建可及性指标体系,定期开展系统评价,同时加强政策宣传教育。 Objective:The paper analyzes the implementation status of"dual channel"management of national negotiated drugs in S Province,and analyzes the factors affecting the availability,so as to provide reference for governments to improve relevant policies and the availability of drugs for patients.Methods:The data were collected from the S Province State-negotiated Drug Monitoring Platform,the official policy documents and reports were investigated,and the availability analysis was conducted using Excel and WHO/HAI standard survey method.Results:The"dual channel"management of state-negotiated drugs in S Province achieved initial results and the overall availability of drugs was improving,but there were differences among institutions and diseases,and the availability of specific varieties was generally low.The factors affecting accessibility included policy coordination,medical institution diagnosis and treatment level and information system construction.Conclusions:It is suggested to improve the construction of medical institutions and coordinate regional development,establish communication and coordination mechanism,strengthen supervision and management,establish an accessibility index system,carry out systematic evaluation on a regular basis,and strengthen policy publicity and education.
出处 《中国医疗保险》 2022年第11期54-59,共6页 China Health Insurance
关键词 双通道 国谈药 WHO/HAI标准调查法 可获得性 dual channel state-negotiated drugs WHO/HAI standard survey method availability
  • 相关文献

参考文献8

二级参考文献63

  • 1WHO, HAI. Medicine prices : a new approach to measure- ment. Working draft for field-testing and revision[DB/OL ]. [2010-03-01].http://www.haiweb.org/medicinepriees/ma- nual/manuals/MedicinePrices.pdf.
  • 2MSH. International Drug Price Indicator Guide[DB/OL ]. [2012-03-08]. http://apps.who.inl/medicinedocs/fr/m/ab- stract/Js 19968en/.
  • 3国家统计局.商品零售价格分类指数[DB/OL].[2012—03—08].http://www.stats.gov.cn/tjsj/.
  • 4OECD.中国购买力平价指数[EB/OL].[2012-03-08].http://stats.oecd.org/Index.aspx?datasetcode:SNA-TA-BLE4.
  • 5Shanti M, Keiko F, Alexandr C, et al. The availability and affordability of selected essential medicines for chron- ic diseases in six low- and middle-income countries[J]. Bulletin of the World Health Organization, 2007,85 (4) : 279.
  • 6HA1. Medicine prices, Availability, Affordability & Price Components[EB/O L ]. [2013-02-02].http://www.haiweb. org/medicineprices.
  • 7Hao Y, Hassan HD, Minmin Z, et al. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China[J]. Health Policy And Planning, 2010,25 (3) :219.
  • 8Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries[J]. Lancet, 2009, 373 (9 659) : 240.
  • 9SFDA.国产药品数据查询[DB/OL].[2012—03-09].http://appl.sfda.gov.cn/datasearch/face3/base.jsp?tableld=25&t-ableName=TABLE25&title=国产药品&bcld=124356560303886909015737447882.
  • 10World Health Organization.The Right to Health[R/OL].[2014-06-08].http://www.refworld.org/docid/48625a742.html.

共引文献142

同被引文献59

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部